Anticancer treatment regimens are effective but may lead to cardiac dysfunction. The meaning of this statement is that myocardial strain can be a good indicator of cancer treatment-related cardiac dysfunction. We used Bayesian network meta-analysis to compare and rank these regimens to comprehensively evaluate their influence on the heart. We searched multiple databases to identify relevant studies. Global longitudinal strain (GLS), global radial strain, global circumferential strain, and other parameters were collected at baseline (T0), from baseline to 3 months of follow-up (T3), from 3 months to 6 months of follow-up (T6), and from 6 months to 12 months or longer of follow-up (T12). The weight mean differences (WMD) with 95% confidence intervals (CI) were used to express continuous variables. Direct and indirect comparison and ranking of different regimens based on the forest plots and the surface under the cumulative ranking area. A total of 4613 subjects were included in 33 studies. Anthracycline-based chemotherapy (ANT), trastuzumab, paclitaxel plus carboplatin or clofarabine, and radiotherapy (RT) were more likely to reduce GLS and global circumferential strain at T3 and T12. In particular, ANT+RT resulted in a more significant decrease in GLS than ANT alone at T12 (WMD 1.15; 95% CI, 0.05-2.26). Interestingly, cardioprotective treatment regimens, such as anthracycline plus bisoprolol plus angiotensin-converting enzyme inhibitors (ANT+BB+ACEIs) (WMD -2.79; 95% CI, -5.06 to -0.52), and ANT plus rosuvastatin (STATINs) (WMD -2.92; 95% CI, -5.54 to -0.29), were more likely to improve GLS than ANT at T12. The included anticancer regimens, especially ANT+RT, reduced GLS at T12, but their combination with cardioprotective drugs improved them. These results will help clinicians choose the best therapy regimens.

中文翻译：

---

通过超声心肌应变综合评估癌症治疗相关的心脏功能障碍：网络荟萃分析。

抗癌治疗方案有效，但可能导致心脏功能障碍。该说法的含义是，心肌应变可以作为癌症治疗相关心脏功能障碍的良好指标。我们利用贝叶斯网络荟萃分析对这些方案进行比较和排序，以综合评价它们对心脏的影响。我们检索了多个数据库来确定相关研究。在基线（T0）、从基线到随访3个月（T3）、从随访3个月到6个月收集全局纵向应变（GLS）、全局径向应变、全局周向应变和其他参数（ T6)，以及 6 个月至 12 个月或更长时间的随访 (T12)。具有 95% 置信区间 (CI) 的权重平均差 (WMD) 用于表示连续变量。根据累积排名面积下的林地和地表，对不同方案进行直接和间接的比较和排名。33 项研究总共纳入了 4613 名受试者。基于蒽环类药物的化疗 (ANT)、曲妥珠单抗、紫杉醇加卡铂或氯法拉滨以及放疗 (RT) 更有可能减少 T3 和 T12 时的 GLS 和整体周向应变。特别是，在 T12 时，ANT+RT 比单独使用 ANT 导致 GLS 下降更显着（WMD 1.15；95% CI，0.05-2.26）。有趣的是，心脏保护治疗方案，例如蒽环类药物加比索洛尔加血管紧张素转换酶抑制剂 (ANT+BB+ACEIs) (WMD -2.79；95% CI，-5.06 至 -0.52)，以及 ANT 加瑞舒伐他汀 (STATIN) (WMD - 2.92；95% CI，-5.54 至 -0.29)，在 T12 时比 ANT 更有可能改善 GLS。所包含的抗癌方案，尤其是 ANT+RT，降低了 T12 时的 GLS，但与心脏保护药物的组合改善了 GLS。这些结果将帮助临床医生选择最佳的治疗方案。